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We completed a real-world analysis of 498 consecutive highrisk nonimmunocompromised and immunocompromised
patients who received sotrovimab during the B.1.1.529
surge. Emergency department visits/hospitalizations and 30-day
all-cause mortality between the 2 groups were similar. When
administered early, sotrovimab is effective at preventing
coronavirus disease 2019 progression in immunocompromised
and nonimmunocompromised patients.
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Coronavirus disease 2019 (COVID-19), caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted
in >5.8 million deaths worldwide and >900 000 deaths in the
United States [1]. Monoclonal antibodies (MABs) have been evaluated to treat COVID-19 in the outpatient setting to prevent disease progression and subsequent hospitalization in high-risk
patients. MABs block the interaction between viral proteins
and human cells, preventing the viral agents from entering the
target cells [2]. They are most effective when utilized early in
COVID-19 [2].
The Omicron (B.1.1.529) variant was ﬁrst detected in
November 2021 and quickly became the dominant SARS-CoV-2
variant [3]. This variant has signiﬁcant mutations, including 37
substitutions in the spike protein, the majority clustered in the
receptor-binding domain (RBD) [3]. The main target of MAB is
the RBD, and these mutations in B.1.1.529 made many MAB therapies ineffective, including the combination therapies casirivamab/imdevimab and bamlanivab/etesevimab [3]. Sotrovimab, an

Received 18 March 2022; editorial decision 27 May 2022; accepted 01 June 2022; published
online 7 June 2022
Correspondence: Navina K. Birk, MD, 2799 West Boulevard, Detroit, MI 48202 (nbirk1@hfhs.
org).
Open Forum Infectious Diseases®
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases
Society of America. This is an Open Access article distributed under the terms of the Creative
Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/
licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the
work, in any medium, provided the original work is not altered or transformed in any way,
and that the work is properly cited. For commercial re-use, please contact journals.permiss
ions@oup.com
https://doi.org/10.1093/oﬁd/ofac282

METHODS

We performed a retrospective analysis of high-risk patients with
COVID-19 who were referred for sotrovimab treatment from
December 27, 2021, to January 3, 2022. All patients were >18
years of age and had a positive SARS-CoV-2 test by polymerase
chain reaction or antigen. All patients received a 500-mg infusion of sotrovimab within 10 days of symptom onset.
High risk was deﬁned as patients with any of the following
conditions identiﬁed in the FDA EUA: age >65 years, body
mass index (BMI) >30, pregnancy, chronic lung disease, diabetes, cardiovascular disease, end-stage renal disease on dialysis,
and immunosuppressive disease or immunosuppressive treatment [5]. Immunocompromised patients were deﬁned as those
with primary immunodeﬁciency, people with HIV, organ transplant recipients, or those receiving chemotherapy, biologic
immunomodulators, immunosuppressive drugs, or high-dose
corticosteroids [6]. Demographic data, underlying comorbidities, and COVID-19 vaccination status were collected. A
descriptive analysis was performed of all consecutive patients
who met study inclusion criteria. The primary outcome was
emergency department (ED) visits and/or hospitalizations,
and the secondary outcome was all-cause mortality. All outcomes were measured at 30 days after administration of sotrovimab. Additionally, we completed a nested case–control
analysis to compare outcomes of immunocompromised
patients with those of nonimmunocompromised patients.
RESULTS

Of the 498 patients who met inclusion criteria, 88 patients were
classiﬁed as immunocompromised and 410 as nonimmunocompromised. Patient characteristics are shown in Table 1.
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engineered human MAB, retained activity against B.1.1.529
through recognition of antigenic sites outside the RBD [3]. The registration clinical trial demonstrated the effectiveness of sotrovimab
in preventing hospitalizations in high-risk COVID-19 patients [4].
However, there are no reports that have examined the effectiveness
speciﬁcally in high-risk immunocompromised patients.
By December 31, 2021, B.1.1.529 became the dominant variant in the United States [1]. At Henry Ford Health System
(HFHS) in Michigan, sotrovimab has been the only MAB administered under Food and Drug Administration (FDA)
Emergency Use Authorization (EUA) since December 27,
2021, due to the rapid increase in cases of B.1.1.529. We report
our real-world experience with sotrovimab in immunocompromised and nonimmunocompromised patients with
COVID-19 at high risk for disease progression.

Table 1. Characteristics and Outcomes in Immunocompromised vs Nonimmunocompromised Patients Receiving Sotrovimab
Total (n = 498)
Male, No. (%)
Age, median (IQR), y
Age >65 y, No. (%)

Immunocompromised (n = 88)

181 (36.3)
64 (40–74)
246 (49.4)

34 (38.6)

Nonimmunocompromised (n = 410)
147 (35.9)

P Value
.622

60.5 (44.5–71)

65 (40–74.75)

.434

210 (51.2)

36 (40.9)

.079

Self-reported race/ethnicity
138 (27.7)

22 (25)

116 (28.3)

.531

White, No. (%)

300 (60.2)

60 (68.2)

240 (58.5)

.093

Other, No. (%)

41 (8.2)

5 (5.7)

36 (8.8)

.337

Unknown, No. (%)

19 (3.8)

1 (1.1)

18 (4.4)

BMI,a median (IQR), kg/m2

31.1 (26.5–39)

29.4 (26.1–34.7)

31.6 (26.6–39.5)

.221
.020

Cardiac risk factors,b No. (%)

315 (63.3)

59 (67.0)

256 (62.4)

.416

Pulmonary risk factors,c No. (%)

160 (32.1)

23 (26.1)

137 (33.4)

.185

Diabetes, No. (%)

115 (23.1)

28 (31.8)

87 (21.2)

CKD/ESRD, No. (%)

62 (12.4)

23 (26.1)

39 (9.5)

Pregnancy, No. (%)

52 (10.4)

2 (2.3)

50 (12.2)

.003

5 (4–7)

.272

Symptoms to dose, median (IQR), d
Vaccinated (≥1 dose), No. (%)
COVID-related ED visit or admission, No. (%)
COVID-related admission, No. (%)

5 (4–7)

5 (4–6.25)

.032
<.001

<.001

334 (67.1)

74 (84.1)

260 (63.4)

11 (2.2)

4 (4.5)

7 (1.7)

.111

8 (1.6)

4 (4.5)

4 (1.0)

.036

COVID-related ED visit, No. (%)

3 (0.6)

0 (0)

3 (0.7)

.421

Death, No. (%)

3 (0.6)

2 (2.3)

1 (0.2)

.082

Abbreviations: BMI, body mass index; CKD, chronic kidney disease; ED, emergency department; ESRD, end-stage renal disease; IQR, interquartile range.
a

Calculated as weight in kilograms divided by height in meters squared.

b

Included myocardial infarction, coronary disease, hyperlipidemia, hypertension, or congestive heart failure.

c

Included asthma, chronic obstructive pulmonary disease, or obstructive sleep apnea.

The immunocompromised group included patients with rheumatological diseases, multiple sclerosis, HIV infection, hematological malignancy, solid organ malignancy, inﬂammatory
bowel disease, interstitial lung disease, and organ transplant recipients. The immunocompromised group had lower median
BMI, higher rates of diabetes, chronic kidney disease or endstage renal disease, lower rates of pregnancy, and were more
likely to be vaccinated. The rest of the demographics and underlying comorbidities were comparable in both groups.
Overall, the primary outcome was met in 11 patients (2.2%),
ED visits in 3 patients (0.6%), and hospital admissions in 8 patients (1.6%). Death occurred in 3 patients (0.6%). In the immunocompromised group, the primary outcome was met in 4
patients (4.5%), compared with 7 patients (1.7%) in the nonimmunocompromised group (P .111). All the immunocompromised patients were hospitalized, compared with 4 patients
(1.0%) in the nonimmunocompromised group (P = .036).
Thirty-day all-cause mortality occurred in 2 patients (2.3%) in
the immunocompromised group, compared with 1 patient
(0.2%) in the nonimmunocompromised group (P = .082). No
immediate adverse events were observed after sotrovimab
administration.

DISCUSSION

Our real-world study of 498 patients demonstrates the effectiveness of sotrovimab in preventing hospitalizations and
2 • OFID • BRIEF REPORT

mortality in immunocompromised and high-risk nonimmunocompromised COVID-19 patients.
Previous studies have not evaluated the effectiveness of sotrovimab, speciﬁcally in immunocompromised patients at high risk for
COVID-19 disease progression. In the COMET-ICE registration
trial [4], of 291 patients administered sotrovimab, 1% of patients
were hospitalized and 0 patients died (Supplementary Table 1).
Compared with our study, overall, 1.6% of patients were hospitalized and 0.6% died. The slightly higher rate of hospitalization and
death in our real-world study can be accounted for by the higher
rate of median comorbidities, older age, and later administration
of sotrovimab. While COMET-ICE patients had a median of 1
high-risk comorbidity, our patients had a median of 3. The median age in COMET-ICE was 53 years, and our patients’ median age
was 64 years. The median time to dose in COMET-ICE was documented as <3 days, and our median time to dose was 5 days.
COMET-ICE did not report on outcomes in immunocompromised patients. We found no signiﬁcant difference in ED visits
and hospitalizations between the immunocompromised and nonimmunocompromised groups. All patients who presented to the
hospital in the immunocompromised group were hospitalized;
however, there was no signiﬁcant difference in 30-day all-cause
mortality between the 2 groups.
Other studies investigating sotrovimab include the TICO trial [7]. This study found no signiﬁcant difference in patients administered sotrovimab compared with placebo; however, the
population studied was hospitalized patients, and sotrovimab
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was administered 8 days from symptom onset, later than an average of 5 days in our population [7].
Our study is limited due to its retrospective nature and limited sample size. Due to logistical issues, we were not able to
compare COVID-19-positive patients who did not receive sotrovimab with those who did. In our study, 67.07% of patients
were vaccinated, and it is unknown what effect this has on studied outcomes. Additionally, we could not analyze the role of
COVID-19 seropositivity in all patients.
We conclude that in a real-world setting, early administration of sotrovimab has low rates of COVID-19 disease progression among high-risk patients, including those who are
immunocompromised.

